Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis Recruiting

2025-521295-60-00 Sporadic Amyotrophic Lateral Sclerosis 1 2026-01-29
Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS Recruiting

2025-520688-42-00 Amyotrophic Lateral Sclerosis (ALS) 4 2026-01-27
A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Day… Recruiting

2025-523612-37-00 Parkinson's Disease and Apathy 3 2026-01-23
A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting

2024-519820-26-00 Hallucinations and Delusions Associated with Alzheimer’ 4 2026-01-22
A Single-Center, Double-Blind, Randomized, Placebo Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and P… Recruiting

2025-523885-25-00 Healthy Volunteers 1 2026-01-21
Study of Oral MC-1 for the Treatment of Patients with PNPO Deficiency Recruiting

2025-522346-46-00 Seizures associated with Pyridox(am)ine 5’-Phosphate Ox 5 2026-01-20
Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-mo… Recruiting

2024-516756-18-00 Parkinson's disease 5 2026-01-19
A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy Recruiting

2025-523469-79-00 Spinal and Bulbar Muscular Atrophy 1 2026-01-16
A Phase 3 Study of JNT-517 in Participants with Phenylketonuria Recruiting

2024-519554-37-00 Phenylketonuria 5 2026-01-16
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
Comparison of Two Pain and Bleeding Control Methods in Back Surgery: A Study on Periarticular Vasoconstrictor Infiltration (PIV) vs. Erector… Recruiting

2025-521572-56-00 lumbar arthrodesis 5 2026-01-08
Exploring Eptinezumab: Unveiling Peripheral and Central Mechanisms of Action and Searching for Biomarkers of Patient Response (EUPHORIA Stud… Recruiting

2024-519337-35-00 Migraine 6 2026-01-08
AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, plac… Recruiting

2025-521686-27-01 Major Depression 4 2026-01-08
Intranasal Cenegermin in Pediatric Participants with Spastic Cerebral Palsy. Recruiting

2025-522786-29-00 Spastic Cerebral Palsy 4 2026-01-07
Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial Recruiting

2025-522506-20-00 Depression 6 2026-01-07
Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou… Recruiting

2025-521144-38-00 Primary Central Nervous System Lymphoma 4 2025-12-23
INFLANET - A French Network for PET imaging of neuroinflammation in MS Recruiting

2023-510304-53-00 Multiple sclerosis 10 2025-12-16
The LESS-AD trial: A study on the use of levetiracetam to prevent seizures in adults with Down syndrome and Alzheimer's disease. Recruiting

2024-516148-24-00 Down syndrome 5 2025-12-16
A randomized, placebo-controlled, double-blind clinical trial evaluating the safety and efficacy of parecoxib in hospitalized patients with … Recruiting

2024-519436-17-00 spontaneous subarachnoid hemorrhage 4 2025-12-15
Pharmacokinetics of NTRX-07 in fed and fasted participants Recruiting

2025-523695-23-00 Not applicable (trial is a pharmacokinetic study in hea 3 2025-12-11
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting

2024-512904-21-00 Migraine 4 2025-12-10
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
Guanabenz in VWM: extension study Recruiting

2024-518834-95-02 Vanishing white matter 9 2025-12-08
A Phase 3 study of Omaveloxolone in participants with Friedreich’s Ataxia Ages 2 < 16 years Recruiting

2025-520896-13-00 Friedreich’s ataxia 5 2025-12-04